Showing results (911-920 of 2,811) with videos related to

Sort By:
Pageof 282
Expert Opinion on Drug Safety|December 16, 2024
Cutaneous toxicity induced by antidepressants and second-generation antipsychotics in the United States food and drug administration adverse event reporting systemYueyue Yuan, Mengting Shen, Chong Chen, et al.
Expert Opinion on Drug Safety|December 23, 2024
Skin cancer associated with calcineurin inhibitors treatment: analysis of FAERS databaseYuezhen Zhu, Hui Yang, Zhuoling An
Expert Opinion on Drug Safety|December 21, 2024
Safety assessment of ezetimibe: real-world adverse event analysis from the FAERS databaseYuchen Han, Siyuan Cheng, Jinzheng He, et al.
Expert Opinion on Drug Safety|December 20, 2024
Hematopoietic adverse events associated with PARP inhibitors: A FAERS database studyQindai Shuai, Xuefei Bai, Gen Li, et al.
Expert Opinion on Drug Safety|December 12, 2024
Vancomycin and linezolid: severe cutaneous adverse reactions to drugsChen-Sui-Zi Li, Mei-Fen Han, Bing Yu, et al.
Expert Opinion on Drug Safety|December 10, 2024
Drug-induced megacolon in schizophrenia: a pharmacovigilance study of antipsychotic medications from the Japanese Adverse Drug Event database: a disproportionality analysisKeita Tokumitsu, Norio Sugawara, Yuki Kondo, et al.
Expert Opinion on Drug Safety|December 14, 2024
Drug-induced dementia: a pharmacovigilance analysis of the FAERS databaseYu Wang, Jiahe Kong, Yi Yang, et al.
Expert Opinion on Drug Safety|December 15, 2024
Cardiovascular adverse events in patients with HER2-positive breast cancer treated with trastuzumab-drug conjugates : a Bayesian disproportional real world study for signal detection leveraging the FDA Adverse Event Reporting System (FAERS)Jinfang Hu, Siyu Chen, Huanhuan Jia, et al.
Expert Opinion on Drug Safety|November 16, 2024
Pharmacovigilance insights into drug-induced cystitis: analysis of FDA data from 2004 to 2024Fuchun Zheng, Xin Yang, Sheng Li, et al.
Expert Opinion on Drug Safety|October 16, 2024
The effectiveness and safety of aripiprazole, bromocriptine, and cabergoline in the treatment of hyperprolactinemia: a systematic review and network meta-analysisKun Ma, Linna Ma, Tianjiao Huang, et al.
Pageof 282